Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P).
R G LangleyKim A PappM GooderhamL ZhangC MallinckrodtN AgadaAndrew BlauveltP FoleyP Polzernull nullPublished in: The British journal of dermatology (2018)
Ixekizumab Q2W had higher efficacy at week 52 than ixekizumab Q4W, with no increase in safety events.